Connor, Clark & Lunn Investment Management Ltd. Abb Vie Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 19,751 shares of ABBV stock, worth $3.42 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

19,751

Previous 16,913 16.78%

Holding current value

$3.42 Million

Previous $2.9 Million 34.48%

% of portfolio

0.02%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$163.84 - $199.33 $464,977 - $565,698	2,838 Added 16.78%	19,751 $3.9 Million
Q2 2024 Aug 09, 2024	SELL	$154.79 - $180.76 $2.61 Million - $3.05 Million	-16,854 Reduced 49.91%	16,913 $2.9 Million
Q1 2024 May 09, 2024	BUY	$159.82 - $182.1 $4.3 Million - $4.9 Million	26,886 Added 390.73%	33,767 $6.15 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $1.63 Million - $1.84 Million	-11,864 Reduced 63.29%	6,881 $1.07 Million
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $18.6 Million - $21.5 Million	-139,056 Reduced 88.12%	18,745 $2.79 Million
Q2 2023 Aug 10, 2023	BUY	$132.51 - $164.9 $19 Million - $23.6 Million	143,281 Added 986.78%	157,801 $21.3 Million
Q1 2023 May 09, 2023	SELL	$144.61 - $166.54 $6.32 Million - $7.28 Million	-43,717 Reduced 75.07%	14,520 $2.31 Million
Q4 2022 Feb 10, 2023	BUY	$138.31 - $165.87 $3.87 Million - $4.64 Million	27,983 Added 92.49%	58,237 $9.42 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $3 Million - $3.44 Million	-22,376 Reduced 42.52%	30,254 $4.06 Million
Q2 2022 Aug 05, 2022	SELL	$137.62 - $174.96 $26.8 Million - $34.1 Million	-194,756 Reduced 78.73%	52,630 $8.06 Million
Q1 2022 May 12, 2022	BUY	$131.98 - $163.75 $17.1 Million - $21.3 Million	129,884 Added 110.54%	247,386 $40.1 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $12.1 Million - $15.3 Million	112,261 Added 2141.98%	117,502 $15.9 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $7.7 Million - $8.75 Million	-72,408 Reduced 93.25%	5,241 $565,000
Q2 2021 Aug 12, 2021	SELL	$105.21 - $117.21 $20.7 Million - $23.1 Million	-196,906 Reduced 71.72%	77,649 $8.75 Million
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $769,091 - $846,677	-7,518 Reduced 2.67%	274,555 $29.7 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $1.49 Million - $2.01 Million	18,499 Added 7.02%	282,073 $30.2 Million
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $20.8 Million - $24.4 Million	242,011 Added 1122.34%	263,574 $23.1 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $1.58 Million - $2.12 Million	21,563 New	21,563 $2.12 Million
Q4 2019 Feb 12, 2020	SELL	$72.13 - $90.25 $4.82 Million - $6.03 Million	-66,850 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$62.98 - $75.72 $10.9 Million - $13.1 Million	-172,425 Reduced 72.06%	66,850 $5.06 Million
Q2 2019 Aug 07, 2019	SELL	$65.7 - $83.98 $7.89 Million - $10.1 Million	-120,050 Reduced 33.41%	239,275 $17.4 Million
Q1 2019 May 08, 2019	SELL	$77.14 - $90.79 $2.92 Million - $3.44 Million	-37,850 Reduced 9.53%	359,325 $29 Million
Q4 2018 Feb 12, 2019	SELL	$77.85 - $96.01 $11.8 Million - $14.5 Million	-151,175 Reduced 27.57%	397,175 $36.6 Million
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $25.5 Million - $28.3 Million	286,725 Added 109.59%	548,350 $51.9 Million
Q2 2018 Aug 02, 2018	BUY	$89.78 - $106.23 $9.55 Million - $11.3 Million	106,350 Added 68.49%	261,625 $24.2 Million
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $12.4 Million - $16.6 Million	134,950 Added 663.96%	155,275 $14.7 Million
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $1.82 Million - $2 Million	20,325	20,325 $1.97 Million

Others Institutions Holding ABBV

# of Institutions

3,852

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $306B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Abb Vie Inc. Transaction History